Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

Florence Joly; Amélie Anota; Sylvie Chabaud; Claire Cropet; Frank Priou; Philipp Harter; Sandro Pignata; Isabel Palacio; Edgar Petru; Hiroaki Kobayashi; Ignace Vergote; Gabriella Parma; Johanna Mäenpää; Eric Raymond; Beyhan Ataseven; Carmela Pisano; Núria Laínez; Irina Tsibulak; Kan Yonemori; Peter Vuylsteke; M. Lapresa; Mansoor Raza Mirza; P. Bouchaert; Paul Buderath; Domenica Lorusso; Ana Herrero; Lauriane Eberst; Alexander Burges; G Scambia; Eugenia Ortega; Cécile Guillemet; Eric Pujade-Lauraine; Jean-Emmanuel Kurtz; Isabelle Ray-Coquard

doi:10.1093/jnci/djag122

Key Points

To evaluate the impact of maintenance olaparib combined with bevacizumab on health-related quality of life in patients with advanced ovarian cancer.
Clinical trial NCT02477644 assessing newly diagnosed advanced ovarian cancer patients.
Measured global health-related quality of life (HRQoL) across populations.
Evaluated HRQoL in both overall population and in HRD-positive subgroup.
No clinically meaningful detrimental effect on global HRQoL observed overall.
HRQoL in the HRD-positive subgroup also showed no significant decline.

Implication

Assesses maintenance olaparib plus bevacizumab impact on quality of life in ovarian cancer, suggesting no significant detriment.

Abstract

Adding maintenance olaparib to bevacizumab showed no clinically meaningful detrimental effect on global HRQoL either overall or in the HRD-positive subgroup. ClinicalTrials.gov ID: NCT02477644.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Joly et al. (2026) studied this question.

synapsesocial.com/papers/69eefd43fede9185760d4053 https://doi.org/10.1093/jnci/djag122

View Full Paper

Ask AI

Bookmark

Share

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

Key Points

Implication

Abstract

Discussion

Cite This Study

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from JNCI Journal of the National Cancer Institute

Keep reading

More related papers

More from JNCI Journal of the National Cancer Institute